Ocugen (NASDAQ:OCGN – Get Rating) is set to announce its earnings results before the market opens on Friday, August 5th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Ocugen (NASDAQ:OCGN – Get Rating) last released its quarterly earnings data on Friday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.14). On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Ocugen Stock Performance
OCGN opened at $2.70 on Thursday. Ocugen has a 12-month low of $1.67 and a 12-month high of $17.65. The stock has a market cap of $582.29 million, a price-to-earnings ratio of -7.94 and a beta of 4.24. The business has a 50 day moving average of $2.44 and a 200-day moving average of $2.82. The company has a quick ratio of 17.96, a current ratio of 17.96 and a debt-to-equity ratio of 0.01.
Insiders Place Their Bets
Hedge Funds Weigh In On Ocugen
A number of hedge funds have recently added to or reduced their stakes in the stock. IHT Wealth Management LLC bought a new position in shares of Ocugen in the 1st quarter valued at $33,000. Mackenzie Financial Corp bought a new position in shares of Ocugen in the 1st quarter valued at $34,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Ocugen in the 1st quarter valued at $47,000. Cetera Investment Advisers bought a new position in shares of Ocugen in the 1st quarter valued at $50,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Ocugen by 344.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 980,928 shares of the company’s stock valued at $3,238,000 after purchasing an additional 760,306 shares during the last quarter. Institutional investors own 39.70% of the company’s stock.
Wall Street Analysts Forecast Growth
OCGN has been the subject of several research reports. Cantor Fitzgerald initiated coverage on Ocugen in a report on Thursday, June 2nd. They set an “overweight” rating and a $4.50 price target for the company. Chardan Capital dropped their price target on Ocugen from $4.00 to $3.50 and set a “neutral” rating for the company in a report on Monday, May 9th. Finally, Roth Capital reissued a “buy” rating and set a $8.00 price target on shares of Ocugen in a report on Wednesday, June 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.80.
Ocugen Company Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.
- Get a free copy of the StockNews.com research report on Ocugen (OCGN)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- PayPal Continues To Struggle As Competition Increases
- Is Starbucks Shooting For The Moon?
- Two High-Yield Deep-Values You Shouldn’t Ignore
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.